Nephrology (Carlton, Vic.) · 2025
Sodium Polystyrene Sulfonate and Heart Failure Risk: A Comparative Study With Calcium Polystyrene Sulfonate.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakayama Takashin, Kaneko Hidehiro, Suzuki Yuta, Okada Akira, Morita Hiroyuki, Fujiu Katsuhito, Takeda Norifumi, Azegami Tatsuhiko, Yokoo Takashi, Takeda Norihiko, Node Koichi, Yasunaga Hideo, Nangaku Masaomi, Hayashi Kaori
Аннотация
AIM: Sodium polystyrene sulfonate (SPS) is one of the classic potassium-binding agents that remains commonly used in the treatment of hyperkalaemia. However, the potential concern about its sodium load has not been fully investigated. In this study, we evaluated the association between SPS initiation and heart failure (HF), compared with calcium polystyrene sulfonate (CPS).
METHODS: This retrospective study enrolled individuals from a nationwide claims database who had been newly prescribed either SPS or CPS between April 2014 and August 2023. The incidence of HF between the two groups was compared using inverse probability of treatment weighting based on the propensity scores.
RESULTS: We analysed 3481 eligible individuals, of whom 478 received SPS and 3003 CPS. Median age (interquartile range) was 78 (71-83) years, 2160 (62%) were male, and median estimated glomerular filtration rate was 47.0 (32.1-63.1) mL/min/1.73 m2. Over a median follow-up of 361 (147-726) days, 709 HF events were documented. Weighted Cox regression analysis demonstrated that SPS users had a higher risk of developing HF (hazard ratio [HR] 1.24; 95% confidence interval [CI] 1.00-1.53). In sub-group analyses, the association of SPS administration with incident HF was more profound in individuals aged ≥ 78 years (HR 1.37; 95% CI 1.05-1.79) than in those aged < 78 years (HR 1.01; 95% CI 0.69-1.48).
CONCLUSION: Our analysis of a nationwide real-world dataset demonstrated that the use of SPS was associated with an increased likelihood of developing HF, suggesting a possible risk related to SPS-induced sodium loading.
METHODS: This retrospective study enrolled individuals from a nationwide claims database who had been newly prescribed either SPS or CPS between April 2014 and August 2023. The incidence of HF between the two groups was compared using inverse probability of treatment weighting based on the propensity scores.
RESULTS: We analysed 3481 eligible individuals, of whom 478 received SPS and 3003 CPS. Median age (interquartile range) was 78 (71-83) years, 2160 (62%) were male, and median estimated glomerular filtration rate was 47.0 (32.1-63.1) mL/min/1.73 m2. Over a median follow-up of 361 (147-726) days, 709 HF events were documented. Weighted Cox regression analysis demonstrated that SPS users had a higher risk of developing HF (hazard ratio [HR] 1.24; 95% confidence interval [CI] 1.00-1.53). In sub-group analyses, the association of SPS administration with incident HF was more profound in individuals aged ≥ 78 years (HR 1.37; 95% CI 1.05-1.79) than in those aged < 78 years (HR 1.01; 95% CI 0.69-1.48).
CONCLUSION: Our analysis of a nationwide real-world dataset demonstrated that the use of SPS was associated with an increased likelihood of developing HF, suggesting a possible risk related to SPS-induced sodium loading.